drug_type
RELEVANT_DRUG
intervention_type
radioimmunotherapy (radiolabeled monoclonal antibody)
drug_description
Radiolabeled anti-PSMA monoclonal antibody variant used for biodistribution and dosimetry assessment, delivering lutetium-177 beta radiation to PSMA-expressing tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Monoclonal, Radiolabeled
drug_category
RADIOIMMUNOCONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Radiolabeled anti-PSMA monoclonal antibody (TLX591 variant, DOTA-chelated to lutetium-177) that binds PSMA on prostate cancer cells and delivers 177Lu beta radiation at the tumor site, causing DNA damage (double-strand breaks) and cell death, with cross-fire effects to nearby PSMA-expressing cells.
drug_name
177Lu-DOTA-TLX591(m17)
nct_id_drug_ref
NCT04876651